🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chennai
Clinical trial register · India

Clinical Trials in Chennai

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 18 Hyderabad 15 Ahmedabad 12 Nagpur 12 Kolkata 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 Eli Lilly and Company10 Novartis Pharmaceuticals5 Janssen Research & Development, LLC4 Bristol-Myers Squibb4 Clear sponsor filter
Site location
New Delhi18 Hyderabad15 Ahmedabad12 Nagpur12 Kolkata12
All 54 locations
Target enrolment
to
4 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
NCT07459543Unresectable Melanoma, Metastatic Melanoma
Bristol-Myers Squibb
Phase 4
40
Nashik, Mumbai, Navi Mumbai, Pune, Bhubaneswar, Chennai, Nagpur, New Delhi
2026-11-15
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
850
Vadodara, Badsa, Gurgaon, Belagavi, Pune, Mohali, Chennai
2026-09-30
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Mumbai, Nagpur, New Delhi, Chennai, Hyderabad, Varanasi
2025-09-11
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 3
606
Gurgaon, Bengaluru, Mumbai, Thane, New Delhi, Mohali, Chennai, Hyderabad
2023-01-10
Rows per page Showing 1–4 of 4
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/chennai

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.